ORBIMED ADVISORS LLC 13D and 13G filings for Enliven Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-05-20 4:55 pm Sale |
2024-05-16 | 13D | Enliven Therapeutics, Inc. ELVN |
ORBIMED ADVISORS LLC | 7,918,163 16.800% |
-1,033,300 (-11.54%) |
Filing |
| 2024-04-04 4:39 pm Purchase |
2024-04-02 | 13D | Enliven Therapeutics, Inc. ELVN |
ORBIMED ADVISORS LLC | 8,951,463 19.200% |
2,124 (+0.02%) |
Filing |
| 2023-02-28 4:00 pm Purchase |
2023-02-23 | 13D | Enliven Therapeutics, Inc. ELVN |
ORBIMED ADVISORS LLC | 8,949,339 21.800% |
8,949,339 (New Position) |
Filing |